After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...